Water soluble gel lubricant on vaginal speculums had no effect on cervical cytology results Amies AM, Miller L, Lee SK, et al 
Main outcome measures
The main outcome measure was unsatisfactory cytology diagnoses. Other cervical cytology results included atypical squamous cells of undetermined significance [ASCUS] , low grade squamous intraepithelial lesion [LGSIL] , high grade SIL [HGSIL] , atypical glandular cells of undetermined significance [AGCUS] , and atypical endometrial cells.
Main results
The intervention and control groups did not differ for the primary outcome (table) or for other cytology results.
Conclusion
In women having Papanicolaou smears, application of water soluble gel lubricant to the plastic vaginal speculum had no effect on the rate of unsatisfactory cervical cytology diagnoses. *See glossary.
†Information provided by author. 
Lubrication v no lubrication for speculums in Papanicolaou smears ‡

COMMENTARY
A few years ago, a senior resident challenged me to produce evidence that vaginal lubricant interfered with cervical cytology results. My literature searches yielded no reports, even though I had been taught not to use lubricant when obtaining a Pap smear because it could affect the quality of the smear. At last, 2 studies have addressed this clinical question. Amies et al randomised 5 family planning clinics to use vaginal lubricant or tap water on the speculum, and found no difference in the rate of unsatisfactory smears. This study had more than 80% power to detect a doubling of the rate of unsatisfactory smears (p < 0.05), so an increase in the rate of unsatisfactory smears would not have been missed. Harer et al randomised 182 women at a single health clinic to vaginal lubricant or tap water, and also found low rates of unsatisfactory Pap smears with no difference between the 2 groups. Although this study had only 70% power to find a difference of 5% in the rate of unsatisfactory smears, the results were consistent with those of Amies et al.
Another teaching that remains with me from medical school is that vaginal lubricant is bacteriostatic and thus interferes with the accuracy of cultures for gonorrhoea or chlamydia. This question is clinically important because sexually transmitted diseases and cervical cancer screening are often done in concert. Evidence on this point is limited, and in vitro studies suggest that further research is needed.
1 DNA probes are often done instead of cultures for screening. A single small study suggests that lubricant is unlikely to have a large effect on chlamydia polymerase chain reaction sensitivity. However, a reduction in sensitivity of 10-20% could not be ruled out.
2 Further research is needed to answer these questions definitively. 
Intervention
Patients were allocated to 2-3 cc surgilube (water soluble lubricant) on the gloved fingers before insertion of an externally lubricated speculum (n=93) or no lubricant other than water on the speculum (n=89).
Main outcome measure
The main outcome measure was an unsatisfactory Papanicolaou smear result.
Main results
The groups did not differ for the primary outcome (table) .
Conclusion
In women having Papanicolaou smears, lubrication of the vaginal introitus and external speculum did not affect cervical cytology results. 
*See glossary.
Lubrication v no lubrication for vaginal speculums in Papanicolaou smears †
COMMENTARY-continued from previous page
Enhancing the comfort of women having speculum examinations is important for both quality of care and public health. More than 50% of women diagnosed with cervical cancer have never been screened or have not had a Pap smear in the previous 3 years. 3 Less discomfort associated with the exam may increase the likelihood that women return for screening at regular intervals. Kudos to Doctors Amies and Harer for addressing this small but important aspect of clinical practice. Their findings have changed my practice and should change the practice of others as well. Patient comfort during Pap smears will affect compliance and may ultimately improve our ability to prevent mortality from cervical cancer.
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